Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 7, 2021; 27(29): 4831-4845
Published online Aug 7, 2021. doi: 10.3748/wjg.v27.i29.4831
Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease
Tiffany Khoo, Danielle Lam, John K Olynyk
Tiffany Khoo, Danielle Lam, John K Olynyk, Department of Gastroenterology and Hepatology, Fiona Stanley Hospital, Murdoch 6150, Australia
Tiffany Khoo, Danielle Lam, John K Olynyk, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Australia
Author contributions: Khoo T and Lam D contributed to the literature review, writing and editing of manuscript; Olynyk JK contributed to editing of manuscript.
Conflict-of-interest statement: The authors declare no conflicts of interest
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: John K Olynyk, FAASLD, AGAF, FRACP, MBBS, MD, Professor, Department of Gastroenterology and Hepatology, Fiona Stanley Hospital, 11 Robin Warren Drive, Murdoch 6150, Australia. john.olynyk@health.wa.gov.au
Received: January 29, 2021
Peer-review started: January 29, 2021
First decision: May 2, 2021
Revised: May 14, 2021
Accepted: July 21, 2021
Article in press: July 21, 2021
Published online: August 7, 2021
Processing time: 187 Days and 3.2 Hours
Core Tip

Core Tip: Hepatitis B and C infection contribute significantly to the global burden of liver disease. With the introduction of modern antiviral therapy, there is now an effective curative treatment for hepatitis C and potent suppressive antiviral therapy for hepatitis B. Antiviral therapy has had a positive impact on liver disease by reducing hospitalisation rates and hence, cost to global health systems. Rates of decompensation, hepatocellular carcinoma and need for transplantation have all been lowered. This review article assesses the literature and summarises the impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes from liver disease.